Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Telitan-AM
- Development stage
- Unknown
- Lead developer
- Meddroid Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Telitan-AM is a fixed-dose combination antihypertensive medication developed and marketed by Meddroid Pharmaceuticals. It consists of two active ingredients: telmisartan, an angiotensin II receptor blocker (ARB), and amlodipine, a dihydropyridine calcium channel blocker (CCB). Telmisartan selectively antagonizes the Angiotensin II receptor type 1 (AT1), preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. Amlodipine inhibits the influx of calcium ions into vascular smooth muscle and cardiac muscle by blocking L-type calcium channels, specifically at the dihydropyridine binding site, which leads to peripheral arterial vasodilation. The combination of these two mechanisms provides a synergistic reduction in peripheral vascular resistance and blood pressure, making it effective for the management of hypertension.
- Brand names
- Telitan-AMTelitan-AM 40Telitan-AM40Telitan-AM-40Telitan-AM 80Telitan-AM80Telitan-AM-80
- Other names
- telmisartan + amlodipinetelmisartan/amlodipineTelmisartan 80mg + Amlodipine 5mgTelmisartan/Amlodipine 80/5
02
Targets
CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AGTR1 (Angiotensin II Type-1 receptor)
Beyond the preview
Go deeper on Telitan-AM.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Telitan-AM.